These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37264710)

  • 21. Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer.
    Li X; Su N; Yu H; Li X; Sun SL
    Cell Commun Signal; 2024 Jul; 22(1):352. PubMed ID: 38970078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells.
    Zhu Y; Wang A; Zhang S; Kim J; Xia J; Zhang F; Wang D; Wang Q; Wang J
    J Adv Res; 2023 Jul; 49():159-173. PubMed ID: 36167294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
    Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
    J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model.
    Tseng LM; Lau KY; Chen JL; Chu PY; Huang TT; Lee CH; Wang WL; Chang YY; Huang CT; Huang CC; Chao TC; Tsai YF; Lai JI; Dai MS; Liu CY
    Exp Cell Res; 2023 Aug; 429(1):113652. PubMed ID: 37209991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
    Ye J; Li R; Yang Y; Dong W; Wang Y; Wang H; Sun T; Li L; Shen Q; Qin C; Xu X; Liao H; Jin Y; Xia X; Liu Y
    J Nanobiotechnology; 2021 Jul; 19(1):199. PubMed ID: 34225762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer.
    Gao T; Sang X; Huang X; Gu P; Liu J; Liu Y; Zhang N
    Acta Pharm Sin B; 2023 Oct; 13(10):4305-4317. PubMed ID: 37799382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chondroitin Sulfate Targeting Nanodrug Achieves Near-Infrared Fluorescence-Guided Chemotherapy Against Triple-Negative Breast Primary and Lung Metastatic Cancer.
    Huang C; Li C; Cai J; Chen J; Wang B; Li M; Zhou W; Wang J; Zhang P; Zhang JV
    Int J Nanomedicine; 2022; 17():5547-5563. PubMed ID: 36444194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-Delivery of Hesperetin and Cisplatin via Hyaluronic Acid-Modified Liposome for Targeted Inhibition of Aggression and Metastasis of Triple-Negative Breast Cancer.
    Wang X; Song Y; Yu L; Xue X; Pang M; Li Y; Luo X; Hua Z; Lu C; Lu A; Liu Y
    ACS Appl Mater Interfaces; 2023 Jul; 15(29):34360-34377. PubMed ID: 37432741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
    Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug.
    Song J; Cheng M; Xie Y; Li K; Zang X
    J Nanobiotechnology; 2023 Mar; 21(1):93. PubMed ID: 36927803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
    Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
    Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
    Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
    Front Immunol; 2022; 13():938439. PubMed ID: 35812418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer.
    Guo B; Qu Y; Sun Y; Zhao S; Yuan J; Zhang P; Zhong Z; Meng F
    Bioact Mater; 2023 Jul; 25():61-72. PubMed ID: 36733927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
    Zhou M; Luo C; Zhou Z; Li L; Huang Y
    J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanodrugs mediate TAMs-related arginine metabolism interference to boost photodynamic immunotherapy.
    Chen Y; Shu X; Guo JY; Xiang Y; Liang SY; Lai JM; Zhou JY; Liu LH; Wang P
    J Control Release; 2024 Mar; 367():248-264. PubMed ID: 38272398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
    Wang Z; Cordova LE; Chalasani P; Lu J
    Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
    Lv Y; Xu C; Zhao X; Lin C; Yang X; Xin X; Zhang L; Qin C; Han X; Yang L; He W; Yin L
    ACS Nano; 2018 Feb; 12(2):1519-1536. PubMed ID: 29350904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.